• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Tuesday

    5/31/22 12:06:15 PM ET
    $ALXO
    $BIG
    $BNR
    $CGA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Department/Specialty Retail Stores
    Consumer Discretionary
    Get the next $ALXO alert in real time by email

     

    On Tuesday, 36 companies achieved new lows for the year.

    Things to Consider About Today's 52-Week Lows:

    • The largest company in terms of market cap to set a new 52-week low was Clearwater Analytics Hldg (NYSE:CWAN).
    • The smallest company in terms of market cap to set a new 52-week low was Genocea Biosciences (NASDAQ:GNCA).
    • Outlook Therapeutics (NASDAQ:OTLK)'s stock fell the most, as it traded down 37.33% to reach a new 52-week low.
    • Burning Rock Biotech (NASDAQ:BNR)'s stock showed potential to rebound, rebounding up 0.69% after reaching a new 52-week low.

    On Tuesday, the following stocks set new 52-week lows:

    • Clearwater Analytics Hldg (NYSE:CWAN) stock broke to a new 52-week low of $14.41 on Tuesday. Shares of the company traded down 5.41%.
    • PTC Therapeutics (NASDAQ:PTCT) stock broke to a new 52-week low of $29.37 on Tuesday. Shares of the company traded down 2.14%.
    • Iovance Biotherapeutics (NASDAQ:IOVA) shares set a new 52-week low of $6.65. The stock traded down 4.13%.
    • Big Lots (NYSE:BIG) shares fell to $24.75 on Tuesday, setting a new 52-week low with a shift of down 7.91%.
    • Community Health Systems (NYSE:CYH) shares moved down 1.48% on Tuesday to hit a new 52-week low of $5.11, drifting down 1.48%.
    • SVF Inv Corp 3 (NASDAQ:SVFC) stock broke to a new 52-week low of $9.26 on Tuesday. Shares of the company traded down 5.31%.
    • LexinFintech Holdings (NASDAQ:LX) shares moved down 16.67% on Tuesday to hit a new 52-week low of $1.89, drifting down 16.67%.
    • Cepton (NASDAQ:CPTN) stock dropped to a yearly low on Tuesday of $2.33. Shares traded down 2.08%.
    • ALX Oncology Holdings (NASDAQ:ALXO) shares set a new 52-week low of $7.50. The stock traded down 5.47%.
    • Theseus Pharmaceuticals (NASDAQ:THRX) stock hit $6.53 on Tuesday morning, setting a new 52-week low for a change of down 1.0%.
    • Burning Rock Biotech (NASDAQ:BNR) stock achieved a new 52-week low on Tuesday morning, hitting $2.34 and moving up 0.69%.
    • Outlook Therapeutics (NASDAQ:OTLK) shares set a new 52-week low of $0.68. The stock traded down 37.33%.
    • Plumas (NASDAQ:PLBC) shares moved down 3.82% on Tuesday to hit a new 52-week low of $27.70, drifting down 3.82%.
    • Natuzzi (NYSE:NTZ) stock drifted down 7.03% on Tuesday morning to hit a new 52-week low of $9.20.
    • Cortexyme (NASDAQ:CRTX) shares hit a yearly low of $2.63. The stock was down 0.74% on the session.
    • Liberty TripAdvisor Hldgs (NASDAQ:LTRPA) shares hit a yearly low of $1.08. The stock was down 8.82% on the session.
    • China Green Agriculture (NYSE:CGA) stock drifted down 8.53% on Tuesday morning to hit a new 52-week low of $6.74.
    • Kirkland's (NASDAQ:KIRK) stock hit a new 52-week low of $5.64. The stock was down 14.16% on the session.
    • Curis (NASDAQ:CRIS) shares set a new yearly low of $0.70 this morning. The stock was down 1.68% on the session.
    • Elevation Oncology (NASDAQ:ELEV) shares fell to $2.12 on Tuesday, setting a new 52-week low with a shift of down 15.84%.
    • Odyssey Marine Explr (NASDAQ:OMEX) shares set a new 52-week low of $3.60. The stock traded down 5.93%.
    • Ocean Power Technologies (AMEX:OPTT) stock hit $0.82 on Tuesday morning, setting a new 52-week low for a change of down 4.59%.
    • Comera Life Sciences (NASDAQ:CMRA) shares fell to $2.45 on Tuesday, setting a new 52-week low with a shift of up 11.2%.
    • Brenmiller Energy (NASDAQ:BNRG) stock set a new 52-week low of $2.75 on Tuesday, moving down 8.77%.
    • MSP Recovery (NASDAQ:MSPR) stock drifted down 21.84% on Tuesday morning to hit a new 52-week low of $1.09.
    • Assure Hldgs (NASDAQ:IONM) shares reached a new 52-week low of $1.59 on Tuesday morning, moving down 5.88%.
    • Kala Pharmaceuticals (NASDAQ:KALA) stock hit a yearly low of $0.34. The stock was down 1.11% for the day.
    • Inspira Technologies Oxy (NASDAQ:IINN) stock achieved a new 52-week low on Tuesday morning, hitting $1.50 and moving down 1.84%.
    • Genocea Biosciences (NASDAQ:GNCA) shares made a new 52-week low of $0.05 on Tuesday. The stock was down 9.03% for the day.

    Be sure to monitor Benzinga for the news traders need! And for even more up-to-date info on 52-week lows and highs, check out Benzinga Pro. This cutting-edge market research platform alerts traders of which stocks are trading near their 52-week highs and lows each morning - and delivers lots of other actionable data. Learn more here.

    Get the next $ALXO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALXO
    $BIG
    $BNR
    $CGA

    CompanyDatePrice TargetRatingAnalyst
    PTC Therapeutics Inc.
    $PTCT
    1/28/2026$119.00Overweight
    Barclays
    Clearwater Analytics Holdings Inc.
    $CWAN
    1/26/2026$24.55Buy → Neutral
    UBS
    Clearwater Analytics Holdings Inc.
    $CWAN
    1/16/2026$24.55Buy → Neutral
    DA Davidson
    Clearwater Analytics Holdings Inc.
    $CWAN
    12/22/2025Outperform → Perform
    Oppenheimer
    Clearwater Analytics Holdings Inc.
    $CWAN
    12/22/2025Outperform → Mkt Perform
    William Blair
    Ocean Power Technologies Inc.
    $OPTT
    12/18/2025$1.50Buy
    H.C. Wainwright
    LexinFintech Holdings Ltd.
    $LX
    12/4/2025$3.50Buy → Neutral
    UBS
    PTC Therapeutics Inc.
    $PTCT
    12/1/2025$91.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $ALXO
    $BIG
    $BNR
    $CGA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

    SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced data demonstrating a best-in-class profile for commercial Amtagvi® (lifileucel) with unprecedented response rates in a real-world clinical, retrospective study in patients with advanced (unresectable or metastatic) melanoma. Amtagvi is the first one-time T cell therapy for a solid tumor cancer as well as the only FDA-approved treatment for advanced melanoma patients previously treated with anti-PD-1 and ta

    2/5/26 5:15:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Natuzzi Received Continued Listing Standard Notice From the NYSE

    The notice has no immediate impact on the listing of the Company's ADRs Natuzzi S.p.A. (NYSE:NTZ) ("Natuzzi" or the "Company") announced today that on January 6, 2026 it received notice from the New York Stock Exchange (the "NYSE") that the Company was no longer in compliance with one of the NYSE's continued listing standards for a listed company (the "NYSE Notice"), because its 30 trading-day average market capitalization and its last reported stockholders' equity as of September 30, 2025 were each below $50 million. Pursuant and subject to the NYSE's rules, the Company has an 18-month cure period following receipt of the NYSE Notice to regain compliance with the NYSE's minimum require

    2/5/26 4:30:00 PM ET
    $NTZ
    Home Furnishings
    Consumer Discretionary

    Clearwater Analytics and TreasurySpring Announce Platform Integration for Fixed-Term Cash Management

    Integration Enables Institutional Clients to Optimize Surplus Cash Returns with Predictable Maturity Matching Clearwater Analytics (NYSE:CWAN), the most comprehensive technology platform for investment management and TreasurySpring, the global cash investment platform, today announced an integration that connects CWAN's investment management platform directly with over 1,000 cash investment products from TreasurySpring, helping institutional clients manage surplus cash with defined maturity requirements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205846318/en/ Through TreasurySpring, institutional clients can: Optimi

    2/5/26 9:00:00 AM ET
    $CWAN
    Computer Software: Prepackaged Software
    Technology

    $ALXO
    $BIG
    $BNR
    $CGA
    SEC Filings

    View All

    SEC Form S-8 filed by Ocean Power Technologies Inc.

    S-8 - Ocean Power Technologies, Inc. (0001378140) (Filer)

    2/6/26 4:18:33 PM ET
    $OPTT
    Electric Utilities: Central
    Utilities

    SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

    6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    2/6/26 9:20:54 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Inspira Technologies Oxy B.H.N. Ltd.

    424B5 - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    2/6/26 9:00:38 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $ALXO
    $BIG
    $BNR
    $CGA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALXO
    $BIG
    $BNR
    $CGA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goodman Corey S bought $4,999,999 worth of shares (3,184,713 units at $1.57) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/4/26 4:15:59 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Stratmann Philipp bought $2,558 worth of shares (7,750 units at $0.33), increasing direct ownership by 2% to 518,440 units (SEC Form 4)

    4 - Ocean Power Technologies, Inc. (0001378140) (Issuer)

    12/16/25 4:05:27 PM ET
    $OPTT
    Electric Utilities: Central
    Utilities

    CFO Powers Robert Patrick bought $5,000 worth of shares (14,723 units at $0.34), increasing direct ownership by 6% to 268,132 units (SEC Form 4)

    4 - Ocean Power Technologies, Inc. (0001378140) (Issuer)

    12/15/25 4:05:12 PM ET
    $OPTT
    Electric Utilities: Central
    Utilities

    $ALXO
    $BIG
    $BNR
    $CGA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on PTC Therapeutics with a new price target

    Barclays resumed coverage of PTC Therapeutics with a rating of Overweight and set a new price target of $119.00

    1/28/26 7:18:18 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearwater Analytics downgraded by UBS with a new price target

    UBS downgraded Clearwater Analytics from Buy to Neutral and set a new price target of $24.55

    1/26/26 8:32:07 AM ET
    $CWAN
    Computer Software: Prepackaged Software
    Technology

    Clearwater Analytics downgraded by DA Davidson with a new price target

    DA Davidson downgraded Clearwater Analytics from Buy to Neutral and set a new price target of $24.55

    1/16/26 8:28:16 AM ET
    $CWAN
    Computer Software: Prepackaged Software
    Technology

    $ALXO
    $BIG
    $BNR
    $CGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director West Daniel E exercised 2,500 shares at a strike of $24.40 (SEC Form 4)

    4 - PLUMAS BANCORP (0001168455) (Issuer)

    2/6/26 1:29:20 PM ET
    $PLBC
    Finance Companies
    Finance

    Director Goodman Corey S bought $4,999,999 worth of shares (3,184,713 units at $1.57) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/4/26 4:15:59 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Powers Robert Patrick was granted 281,965 shares, increasing direct ownership by 24% to 1,474,679 units (SEC Form 4)

    4 - Ocean Power Technologies, Inc. (0001378140) (Issuer)

    1/30/26 4:15:18 PM ET
    $OPTT
    Electric Utilities: Central
    Utilities

    $ALXO
    $BIG
    $BNR
    $CGA
    Financials

    Live finance-specific insights

    View All

    PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

    WARREN, N.J., Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 financial results and provide an update on the company's business and outlook on Thursday, Feb. 19, 2026, at 4:30 p.m. ET. To access the call by phone, please click here to register and you will be provided with dial-in details. The webcast conference call can be accessed on the Investors section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call w

    2/5/26 8:00:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearwater Analytics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026

    Clearwater Analytics Holdings, Inc. (NYSE:CWAN), ("CWAN" or the "Company"), the most comprehensive technology platform for investment management, will release financial results for the fourth quarter and full year ended December 31, 2025 after the U.S. financial markets close on Wednesday, February 18, 2026. As a result of the execution of a definitive agreement under which an investor group led by Permira and Warburg Pincus will acquire all of the outstanding shares of the Company's common stock in an all-cash transaction, as announced on December 21, 2025, the Company will not host an earnings conference call or webcast to discuss its fourth quarter and full year 2025 financial results

    2/4/26 4:15:00 PM ET
    $CWAN
    Computer Software: Prepackaged Software
    Technology

    Community Health Systems to Webcast Fourth Quarter and Year-End 2025 Conference Call

    Community Health Systems, Inc. (NYSE:CYH) today announced that it will webcast its fourth quarter and year-end 2025 conference call. The Company will issue a press release announcing its results on Wednesday February 18, 2026, after the regular close of trading. The conference call is scheduled to begin at 10:00 a.m. Central Time, 11:00 a.m. Eastern Time, on Thursday, February 19, 2026. During this call, Community Health Systems will review the Company's financial and operating results for the fourth quarter and full year ended December 31, 2025. A live webcast of the conference call will be available online at https://www.chs.net/investor-relations/investor-tools/webcasts/. An online r

    2/4/26 11:00:00 AM ET
    $CYH
    Hospital/Nursing Management
    Health Care

    $ALXO
    $BIG
    $BNR
    $CGA
    Leadership Updates

    Live Leadership Updates

    View All

    Morning Market Pulse: AI, Autonomy, and National Security Drive the Narrative at the Open

    DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are waking up to a distinctly forward-looking tape, with investors parsing developments that point to shifts in Artificial Intelligence infrastructure, advanced sensing, defense-aligned energy systems, and deep-tech R&D platforms. Envirotech Vehicles (NASDAQ:EVTV): Strategic Pivot Toward AI Infrastructure Envirotech Vehicles is in focus after announcing an amended and restated Letter of Intent to acquire AZIO AI Corporation, a move that could dramatically reshape the company's long-term identity. The proposed all-equity transaction values AZIO AI at an assumed enterprise value of $480 million, using a $3.00 per share reference price for E

    1/6/26 9:52:32 AM ET
    $AEVA
    $EVTV
    $OPTT
    Auto Parts:O.E.M.
    Consumer Discretionary
    Electric Utilities: Central
    Utilities

    Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

    ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. "We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. "Laura's two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value

    1/6/26 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New Credit Leadership at Plumas Bank Reinforces Strength, Experience and Growth

    QUINCY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Plumas Bank, a wholly-owned subsidiary of Plumas Bancorp, has announced recent changes to its credit administration leadership team. Effective Jan. 1, 2026, Kevin Kaiser, formerly senior vice president and credit administrator, has been promoted to executive vice president and chief credit officer. In addition, Ryan Riggan, formerly senior vice president and SBA credit manager, has assumed the role of credit administrator. Former Executive Vice President and Chief Credit Officer Jeff Moore announced his planned career retirement in October 2025, and Kaiser was named his successor. Moore's last day was December 31, 2025. Kaiser, who joined

    1/2/26 9:00:00 AM ET
    $PLBC
    Finance Companies
    Finance

    $ALXO
    $BIG
    $BNR
    $CGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ocean Power Technologies Inc.

    SC 13G/A - Ocean Power Technologies, Inc. (0001378140) (Subject)

    11/27/24 1:43:24 PM ET
    $OPTT
    Electric Utilities: Central
    Utilities

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:50:19 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 7:22:54 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care